Professor Dimitrios Lamprou (Ph.D. MBA) is a subject matter expert in emerging technologies for drug delivery systems and medical implants. He is the author of over 170 peer-reviewed publications and of over 450 conference abstracts, has over 200 Invited talks in institutions and conferences across the world, and has secure Funding in excess of £5M. Dimitrios, has been recognized as world leader in 3D Printing & Microfluidics. PubMed-based algorithms placed him in the top 0.01% of scholars in the world writing about Printing and in the top 0.07% of scholars in the world writing about microfluidics, over the past 10 years. Dimitrios, has also been named in the Stanford list of World's Top 2% of scientists, for several consecutive years, for his research in Pharmaceutics and Biomedical Engineering. His research and academic leadership have been recognized in a range of awards, including the Royal Pharmaceutical Society (RPS) Science Award, Scottish Universities Life Sciences Alliance (SULSA) Leaders Scheme Award, and Doctor Honoris Causa Award by Semmelweis University (Hungary).

Parasitologist by training and spent over 20 years working on cerebral malaria and its impact on the Blood-Brain-Barrier and Blood-Cerebrospinal Fluid Barrier using a variety of 2D and 3D methods. Also actively researching the impact of neurotropic strains of borrelia to understand how they interact with the BBB and B-CSFB. Interested  more broadly in the role of the peripheral immune system in barrier dysfunction. 

As much as I love doing research, I feel great aversion doing it at the cost of countless animals being sacrificed. Being a passionate advocate of ethical and sustainable research practices, I am fascinated by the idea of using alternative in vitro platforms to reduce and ultimately replace animal testing methodologies. While I acknowledge the historical significance of animal testing and the complex physiological interactions that they provide, I firmly believe that the rapid advancements in the field of biomedical research and development of in vitro testing platforms such as microphysiological systems, organoids, 3D bioprinting offer a more humane and robust approach for toxicological assessments.

PhD-level Tissue Engineer, science communicator, aspiring analyst developer. Experienced in pluripotent stem cells (iPSC), 2D/3D cell culture, organoids, in vitro cardiovascular biology and organ-on-a-chip applications. Passionate about alternatives to animal models following the 3R principle, and science communication to non-experts and general audience. Nowadays taking on new challenges as an analyst developer in the fintech industry, while keeping close ties with the scientific community and the exciting advancements in organoids and NAMs.